Abstract

To evaluate the predictive role of a risk of malignancy index in discriminating between benign and malignant adnexal masses preoperatively. A total of 408 patients with adnexal masses managed surgically between January 2010 and February 2014 were included. The risk of malignancy indices (RMI) 1, 2, 3 and 4 were calculated using findings for ultrasonography, menopausal status, and CA125 levels. Histopathologic results were the end point. ROC analysis was used for the sensitivity and the specificity of the models. Some 37.6 % of the cases were malignant in the postmenopausal group while 7.9 % were malignant in the premenopausal group. Pelvic pain was the most common complaint, and the majority of the cases were diagnosed at stage 3. The RMI 1, 2, 3 and 4 yielded percentage sensitivities of 76.1, 79.1, 76.1 and 76.1 and specificities of 91.5, 89.1, 90.6, 88.6, respectively. RMI 1 was the most reliable test in the general population according to AUC levels and Kappa statistics. From ROC analysis results of post/ premenopausal women, the RMI 1 (cut off: 200) yielded sensitivities of 84.0/60.9 and specificities of 87.7/92.5. With RMI 2 they were 88.6/60.9 and 80.0/91.0, with RMI 3 84.0/ 60.9 and 87.7/91.8, and with RMI 4 (cut off:400) 81.8/47.8 and 83.6 /44.0. Although test performance of RMI methods were good in a general population and postmenopausal women, the RMI inter-agreement validity was only moderate or fair in premenopausal women. Our study confirms the effectiveness of RMI algorithms in postmenopausal women. However, more sensitive tests are needed for premenopausal women.

Highlights

  • Adnexal masses are a problem frequently encountered in gynecological practice

  • Our study confirms the effectiveness of risk of malignancy indices (RMI) algorithms in postmenopausal women

  • This study evaluated the predictive value of four RMI calculations in pre and postmenopausal Turkish women

Read more

Summary

Introduction

Adnexal masses are a problem frequently encountered in gynecological practice. To differentiate the ovarian mass that is benign or malign could change clinical approach. According to data from the United States; each year about 300,000 women are hospitalized because of adnexal masses. According to the American Cancer Society data; more than 21000 new cases will be diagnosed in 2014-2015 and approximately 14000 women will die because of ovarian cancer (Siegel et al, 2014). The 5-year survival rate is about 30% of patients diagnosed with advanced stage. Whereas in the cases diagnosed at an early stage, the 5-year survival rate is about 90% (Su et al, 2013). Results: Some 37.6 % of the cases were malignant in the postmenopausal group while 7.9 % were malignant in the premenopausal group. From ROC analysis results of post/ premenopausal women, the RMI 1 (cut off: 200) yielded sensitivities of 84.0/60.9 and specificities of 87.7/92.5.

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.